Please login to the form below

Not currently logged in
Email:
Password:

People, October, 2010

Recent high-profile moves in the pharmaceutical and healthcare industries
Mover of the month is Simon Dingemans who has been appointed chief financial officer designate and executive director of GlaxoSmithKline with effect from January 2011

Mover of the month

 Simon Dingemans
 

GlaxoSmithKline (GSK) has announced that Simon Dingemans will take up the roles of chief financial officer (CFO) designate and executive director with effect from January 2011. Simon replaces Julian Heslop, who will retire from his role as chief financial officer and executive director at the end of March 2011. Simon joins GSK from investment bank Goldman Sachs. During his 25-year career in investment banking, Simon has worked across multiple sectors, including pharmaceuticals and consumer healthcare. Recently, he worked with GSK on its joint project with Pfizer to establish specialist HIV company ViiV Healthcare.

Fleishman-Hillard has appointed Henry Featherstone as senior policy adviser to its London healthcare public affairs & corporate communications team. Henry joins from the think-tank Policy Exchange, where, as head of the health & social care unit, he authored a series of landmark policy reports, with a number of his recommendations being directly adopted by the Government. Henry had previously spent several years working in Parliament for a number of Conservative politicians. Most recently he was chief of staff to James Arbuthnot MP, chairman of the defence select committee.

Henry Featherstone

Christopher Ehinger  

Christopher Ehinger, formerly oncology and neurology global marketing director for GE Healthcare, has joined Black Swan Analysis as managing director of operations and marketing.

Prism Ideas has appointed Nigel Brooksby as non-executive chairman. Nigel has more than 35 years' experience in the life sciences industry, including his role as chairman and managing director of sanofi-aventis UK and former head of the ABPI. In May this year, the secretary of state for the department for Business, Innovation and Skills (BIS) appointed him as a member of the Industrial Development Advisory Board. Michael Vaughan has also joined Prism as finance director. Michael, a chartered accountant, was most recently European financial controller at Wolters Kluwer Health.


 Nigel BrooksbyMichael Vaughan



4Sight - Laura, Jonathan and Claire

4Sight has made three high level appointments at its global headquarters in Bracknell. Jonathan Hartless joins as operations director from an agency of the Ministry of Defence, where he was head of recruitment and HR operations. Claire Thomas, who has over 15 years' pharma sales experience, joins as programme manager and Laura Crane joins from Origens Financial Services as finance manager.

The MSI Consultancy has appointed Dan Heapy as a consultant. Dan joins MSI from MSD, where over five years he held a number of roles, including marketing manager for both the pain and inflammation and allergy and respiratory portfolios, regional manager primary care, and senior brand manager for Remicade. Prior to this he worked in marketing at AstraZeneca UK and GlaxoSmithKline.


Dan Heapy

 

 

Rachel Vrettos


Red Door Communications (RDC) has made two senior appointments to its consumer health division: Rachel Vrettos has returned from maternity leave to become head of consumer health and Vicky Lygoe has joined from Edelman JCPR as a senior account manager.

 

Dan Blomfield has become an account executive at Adventis Health and Steven Busuttil has joined the digital team as interactive designer.


Adentis - Dan and Steven

 

Synexus has appointed Dr Christophe Berthoux as chief executive. Dr Berthoux joins from Charles River, where he was EVP global sales & marketing and chief commercial officer. Michael Fort, the existing CEO, will become full-time executive deputy chairman. Dr Glynis Neagle has been appointed chief medical officer. Dr Neagle joins from Norgine, where she was director of clinical development.

Bristol-Myers Squibb (BMS) has appointed Patrick Hopkinson to the role of director, market access & eternal affairs in the UK. Patrick joins BMS from GlaxoSmithKline (GSK), where he spent 14 years in various commercial roles, most recently as director, portfolio and partnership marketing.

Asterand has appointed Dalia Cohen chief scientific officer (CSO). Dr Cohen joins Asterand from Rosetta Genomics, a developer of microRNA-based molecular diagnostics, where she currently serves as CSO.

Paul Phull has joined PharmaVentures as senior director. Paul, who has more than 24 years of senior level commercial, business/corporate development and general management experience in the pharmaceutical, biotechnology and medical device industries, joins PharmaVentures from Sinclair Pharma, where he was responsible for the development of the international business with a marketing partner network spanning over 80 countries.

Eli Lilly has named Jeffrey A Winton as its new vice president of communications. Jeffrey joins from West Mill Consulting, where he was founder and managing partner. While at West Mill, he served as interim head, communications and public relations for Bayer Healthcare Pharmaceuticals. Jeffrey, who will serve as a member of the company's global corporate affairs leadership team, will assume his new role at Lilly on October 11.

Dr Siân Walker and Dr Nick Broughton have launched Pharmaceuticalethics.com, providing promotional compliance audit, education and consultancy services to pharma and allied agencies. Former medical and regulatory directors Siân and Nick are joined by Dr Lorraine McMurdo as director of professional standards, and Chris Brinsmead and Dr Susan Bews as consultants.

UniversalProcon has appointed five new members of staff in its UK meetings and events division. New project managers Sophie Limbert and Felicity Jackson join from P&MM and Zibrant, respectively. Rohanna Burrow joins the operations team as an events project executive, and Carly Moon and Lizzie Craig have been appointed event co-ordinators. Lynsey Collier has also been appointed to the newly created role of sales and communications manager. Most recently Lynsey headed up the pitch team at Zibrant.

Clare Nolan and Jon Beck have launched The Recognition Academy. Delivering non-product related education for physicians about pharma industry collaborations, the Recognition Academy is a new partnership company that helps physicians and pharma organisations work together.

The MSI Consultancy has appointed Dan Heapy as a consultant. Dan joins MSI from MSD, where over five years he held a number of roles, including marketing manager for both the pain and inflammation and allergy and respiratory portfolios, regional manager primary care, and senior brand manager for Remicade. Prior to this he worked in marketing at AstraZeneca UK and GlaxoSmithKline.

Rob Jones has been appointed senior account manager at Pegasus. Rob, who has over seven years' experience from his previous work at Munro & Forster, Ruder Finn and MS&L, joins Pegasus permanently after freelancing at the agency for eight months.

Insight Research Group has announced two new appointments to its field team: Eva Oller and Sophie Jacquemin, who join as field executives. Eva joins from Kantar Health, where she was a fieldwork project manager, and Sophie joins from FieldFacts Worldwide, where she held the post of international senior project manager.

Dr Kevin Johnson has joined Index Ventures as a partner in the life sciences team, having worked with the team as a venture advisor since 2004. Dr Johnson has previously worked at Cambridge Antibody Technology (CAT), where he held various roles including chief technology officer, and PanGenetics, where he was chief executive officer.

Jango Communications has made two new appointments. Rebecca Thomas has moved into the role of senior account director and Mystique Offer has been promoted to account executive.

SCRIP Intelligence, formerly SCRIP World Pharmaceutical News, has appointed Mike Ward as editor. Mike joins the team with more than 25 years of editorial experience in the science, pharma and biotech space. In 2006, he was shortlisted by Nature Biotechnology for making a significant contribution to biotech in the previous 10 years and he was nominated as Mediscience Commentator of the Year in both 2009 and 2010, winning in 2010.

The board of the BioIndustry Association (BIA) has elected Tim Edwards, chief executive officer of Cellzome, as its new chairman. Mr Edwards succeeds Dr Clive Dix, who steps down following two and a half years as BIA chairman but will remain a member of the BIA board. Tim  delivered an introductory presentation at the BIA BioLeadership Conference on September 16.

 

Related links

FAQ: How do I get my move listed

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics